학술논문
Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.
Document Type
Article
Author
Mariotto, Sara; Ferrari, Sergio; Monaco, Salvatore; Benedetti, Maria; Schanda, Kathrin; Alberti, Daniela; Farinazzo, Alessia; Capra, Ruggero; Mancinelli, Chiara; Rossi, Nicola; Bombardi, Roberto; Zuliani, Luigi; Zoccarato, Marco; Tanel, Raffaella; Bonora, Adriana; Turatti, Marco; Calabrese, Massimiliano; Polo, Alberto; Pavone, Antonino; Grazian, Luisa
Source
Subject
*MYELIN oligodendrocyte glycoprotein
*HEREDITARY central nervous system demyelinating diseases
*BIOLOGICAL tags
*IMMUNOGLOBULIN G
*IMMUNOGLOBULIN analysis
*THERAPEUTICS
*
*
*
*
*
Language
ISSN
0340-5354
Abstract
Anti-myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) recently emerged as a potential biomarker in patients with inflammatory demyelinating diseases of the central nervous system. We here compare the clinical and laboratory findings observed in a cohort of MOG-Ab seropositive and seronegative cases and describe IgG subclass analysis results. Consecutive serum samples referred to Verona University Neuropathology Laboratory for aquaporin-4 (AQP4)-Ab and/or MOG-Ab testing were analysed between March 2014 and May 2017. The presence of AQP4-Ab was determined using a cell-based assay. A live cell immunofluorescence assay was used for the detection of MOG-IgG and IgG subclass analysis. Among 454 analysed samples, 29 were excluded due to AQP4-Ab positivity or to the final demonstration of a disorder not compatible with MOG-Ab. We obtained clinical data in 154 out of 425 cases. Of these, 22 subjects resulted MOG-Ab positive. MOG-Ab positive patients were mainly characterised by the involvement of the optic nerve and/or spinal cord. Half of the cases presented relapses and the recovery was usually partial. Brain MRI was heterogeneous while short lesions were the prevalent observation on spinal cord MRI. MOG-Ab titre usually decreased in non-relapsing cases. In all MOG-IgG positive cases, we observed IgG1 antibodies, which were predominant in most subjects. IgG2 (5/22), IgG3 (9/22) and IgG4 (3/22) antibodies were also detectable. We confirm that MOG-Ab-related syndromes have distinct features in the spectrum of demyelinating conditions, and we describe the possible role of the different IgG subclasses in this condition. [ABSTRACT FROM AUTHOR]